West Nile Virus DNA Vaccine Enters Human Trial

Vical has announced that initial human testing of an investigational vaccine targeting West Nile virus has begun at the NIH's Clinical Center in Bethesda, Md.

The vaccine, based on Vical's proprietary DNA delivery technology, was co-developed at the National Institute of Allergy and Infectious Diseases' Vaccine Research Center and at Vical. Vical manufactured research and clinical supplies of the vaccine, and has an option to exclusive commercialization rights.